News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
281,731 Results
Type
Article (14904)
Company Profile (299)
Press Release (266522)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (79836)
Career Advice (162)
Deals (13337)
Drug Delivery (39)
Drug Development (50703)
Employer Resources (31)
FDA (5837)
Job Trends (5168)
News (145081)
Policy (10071)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (920)
Accelerated approval (19)
Adcomms (14)
Allergies (83)
Alliances (21761)
ALS (126)
Alzheimer's disease (1033)
Antibody-drug conjugate (ADC) (242)
Approvals (6031)
Artificial intelligence (264)
Autoimmune disease (117)
Automation (9)
Bankruptcy (105)
Best Places to Work (4560)
BIOSECURE Act (6)
Biosimilars (100)
Biotechnology (230)
Bladder cancer (101)
Brain cancer (46)
Breast cancer (345)
Cancer (3144)
Cardiovascular disease (239)
Career advice (147)
Career pathing (7)
CAR-T (221)
CDC (5)
Cell therapy (571)
Cervical cancer (14)
Clinical research (43700)
Collaboration (1161)
Company closure (2)
Compensation (599)
Complete response letters (40)
COVID-19 (1101)
CRISPR (86)
C-suite (559)
Cystic fibrosis (112)
Data (4343)
Denatured (15)
Depression (93)
Diabetes (256)
Diagnostics (1381)
Digital health (12)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (195)
Drug pricing (48)
Drug shortages (3)
Duchenne muscular dystrophy (216)
Earnings (31652)
Editorial (25)
Employer branding (4)
Employer resources (29)
Events (51684)
Executive appointments (625)
FDA (7597)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (10)
Frontotemporal dementia (22)
Funding (990)
Gene editing (182)
Generative AI (22)
Gene therapy (493)
GLP-1 (507)
Government (1148)
Grass and pollen (3)
Guidances (166)
Healthcare (6611)
HIV (18)
Huntington's disease (43)
IgA nephropathy (74)
Immunology and inflammation (192)
Immuno-oncology (42)
Indications (68)
Infectious disease (1207)
Inflammatory bowel disease (156)
Inflation Reduction Act (10)
Influenza (39)
Intellectual property (167)
Interviews (18)
IPO (7346)
IRA (12)
Job creations (867)
Job search strategy (129)
JPM (40)
Kidney cancer (9)
Labor market (22)
Layoffs (243)
Leadership (9)
Legal (1400)
Liver cancer (41)
Longevity (11)
Lung cancer (423)
Lymphoma (250)
Machine learning (24)
Management (7)
Manufacturing (379)
MASH (131)
Medical device (2664)
Medtech (2673)
Mergers & acquisitions (6621)
Metabolic disorders (731)
Multiple sclerosis (104)
NASH (13)
Neurodegenerative disease (233)
Neuropsychiatric disorders (70)
Neuroscience (1960)
Neurotech (1)
NextGen: Class of 2026 (2034)
Non-profit (866)
Now hiring (31)
Obesity (332)
Opinion (125)
Ovarian cancer (132)
Pain (102)
Pancreatic cancer (161)
Parkinson's disease (232)
Partnered (12)
Patents (302)
Patient recruitment (335)
Peanut (44)
People (26669)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15485)
Phase 2 (20306)
Phase 3 (12825)
Pipeline (3308)
Policy (90)
Postmarket research (853)
Preclinical (6539)
Press Release (30)
Prostate cancer (146)
Psychedelics (50)
Radiopharmaceuticals (238)
Rare diseases (657)
Real estate (1448)
Recruiting (12)
Regulatory (9909)
Reports (19)
Research institute (972)
Resumes & cover letters (18)
Rett syndrome (24)
RNA editing (21)
RSV (16)
Schizophrenia (123)
Series A (183)
Series B (140)
Service/supplier (1)
Sickle cell disease (77)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2006)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (18)
The Weekly (62)
Vaccines (337)
Venture capital (69)
Weight loss (174)
Women's health (26)
Worklife (2)
Date
Today (74)
Last 7 days (339)
Last 30 days (1245)
Last 365 days (17876)
2026 (1819)
2025 (18098)
2024 (20543)
2023 (22414)
2022 (26822)
2021 (27805)
2020 (23356)
2019 (16224)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (154)
Alabama (65)
Alaska (2)
Arizona (71)
Arkansas (5)
Asia (18267)
Australia (3112)
California (7104)
Canada (1845)
China (780)
Colorado (248)
Connecticut (252)
Delaware (236)
Europe (39194)
Florida (906)
Georgia (209)
Hawaii (2)
Idaho (17)
Illinois (395)
India (36)
Indiana (161)
Iowa (8)
Japan (227)
Kansas (80)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (737)
Massachusetts (5607)
Michigan (110)
Minnesota (247)
Mississippi (3)
Missouri (32)
Montana (16)
Nebraska (5)
Nevada (32)
New Hampshire (21)
New Jersey (1651)
New Mexico (13)
New York (1770)
North Carolina (831)
North Dakota (6)
Northern California (3495)
Ohio (179)
Oklahoma (11)
Oregon (24)
Pennsylvania (1283)
Puerto Rico (9)
Rhode Island (25)
South America (215)
South Carolina (9)
Southern California (2815)
Tennessee (40)
Texas (915)
United States (23428)
Utah (97)
Virginia (136)
Washington D.C. (37)
Washington State (592)
West Virginia (1)
Wisconsin (46)
281,731 Results for "foghorn therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit
February 3, 2026
·
1 min read
Press Releases
Yatiri Bio Accurately Predicts AML Drug Response in Blinded Study Using Foghorn’s FHD-286
February 10, 2026
·
3 min read
Press Releases
Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium
January 14, 2026
·
2 min read
Press Releases
Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026
January 12, 2026
·
10 min read
Press Releases
Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
November 26, 2025
·
1 min read
Press Releases
Foghorn Therapeutics to Participate in Three Upcoming November 2025 Investor Conferences
November 4, 2025
·
1 min read
Press Releases
Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update
November 5, 2025
·
11 min read
Press Releases
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
August 28, 2025
·
1 min read
Press Releases
Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs
October 31, 2025
·
6 min read
Press Releases
Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit
October 17, 2025
·
3 min read
1 of 28,174
Next
